Patents by Inventor Stephen H Trulli
Stephen H Trulli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9085622Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.Type: GrantFiled: September 2, 2011Date of Patent: July 21, 2015Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Neil James Clarke, Kyung Oh Johanson, Zdenka Ludmila Jonak, Alexander H. Taylor, Christopher B. Hopson, Stephen H. Trulli, Zdenka Haskova, Judithann M. Lee, John R. White, Yu Xue
-
Publication number: 20130156779Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.Type: ApplicationFiled: September 2, 2011Publication date: June 20, 2013Inventors: Neil James Clarke, Kyung Oh Johanson, Zdenka Ludmila Jonak, Alexander H. Taylor, Christopher B. Hopson, Stephen H. Trulli, Zdenka Haskova, Judithann M. Lee, John R. White, Yu Xue
-
Publication number: 20100196310Abstract: The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents.Type: ApplicationFiled: March 20, 2008Publication date: August 5, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Zdenka Haskova, Zdenka Ludmila Jonak, Stephen H. Trulli, Margaret N. Whitacre
-
Publication number: 20100111945Abstract: The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody.Type: ApplicationFiled: March 20, 2008Publication date: May 6, 2010Inventors: Zdenka Haskova, Zdenka Ludmila Jonak, Stephen H. Trulli, John F. Toso, Margaret N. Whitacre
-
Publication number: 20090035258Abstract: The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents.Type: ApplicationFiled: March 20, 2008Publication date: February 5, 2009Inventors: Zdenka Haskova, Zdenka Ludmila Jonak, Stephen H. Trulli, Margaret N. Whitacre
-
Publication number: 20080318835Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: February 29, 2008Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett, Gregg A. Hastings
-
Publication number: 20080312146Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: May 21, 2007Publication date: December 18, 2008Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center, SmithKline Beecham Corp.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20080274078Abstract: The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody.Type: ApplicationFiled: March 20, 2008Publication date: November 6, 2008Inventors: Zdenka HASKOVA, Zdenka Ludmila JONAK, Stephen H. TRULLI, John F. TOSO, Margaret N. WHITACRE
-
Patent number: 7220557Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: GrantFiled: August 13, 1999Date of Patent: May 22, 2007Assignees: Human Genome Sciences, Inc., Beth Israel-Deaconess Medical Center, SmithKline Beecham CorporationInventors: Gregg A. Hastings, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Patent number: 7087405Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human ?v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.Type: GrantFiled: May 9, 2002Date of Patent: August 8, 2006Assignee: SmithKline Beecham CorporationInventors: Kyung O Johanson, Zdenka Ludmila Jonak, Alexander Taylor, Stephen H Trulli
-
Publication number: 20040175794Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: January 15, 2004Publication date: September 9, 2004Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
-
Publication number: 20040072227Abstract: Human Mindin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Mindin polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: ApplicationFiled: July 29, 2003Publication date: April 15, 2004Inventors: Zdenka L. Jonak, Stephen H. Trulli, Ping Tsui, Pamela A. Lane
-
Publication number: 20040002449Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: November 21, 2001Publication date: January 1, 2004Applicant: Human Genome Sciences, Inc.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20030166065Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: April 4, 2002Publication date: September 4, 2003Applicant: Human Genome Sciences, Inc.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
-
Publication number: 20030092900Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: August 13, 1999Publication date: May 15, 2003Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jorak, Stephen H. Trulli, James A. Fronwald, Jonathan A. Terret
-
Publication number: 20030004317Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human &agr;v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.Type: ApplicationFiled: May 9, 2002Publication date: January 2, 2003Applicant: SmithKline Beecham CorporationInventors: Kyung O. Johanson, Zdenka Ludmila Jonak, Alexander Taylor, Stephen H. Trulli
-
Patent number: 6160099Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.Type: GrantFiled: November 24, 1998Date of Patent: December 12, 2000Inventors: Zdenka Ludmila Jonak, Alexander Taylor, Stephen H Trulli, Kyung O Johanson